基于免疫基因的宫颈癌预后标志物的开发与验证

Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer.

作者信息

Chen Yu, Lin Hao, Pi Ya-Nan, Chen Xi-Xi, Zhou Hu, Tian Yuan, Zhao Wei-Dong, Xia Bai-Rong

机构信息

Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Graduate School, Benbu Medical College, Benbu, China.

出版信息

Front Oncol. 2021 Mar 17;11:616530. doi: 10.3389/fonc.2021.616530. eCollection 2021.

DOI:10.3389/fonc.2021.616530

PMID:33842318

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8029986/

Abstract

BACKGROUND

Cervical cancer is one of the most common types of gynecological malignancies worldwide. This study aims to develop an immune signature to predict survival in cervical cancer.

METHOD

The gene expression data of 296 patients with cervical cancer from The Cancer Genome Atlas database (TCGA) and immune-related genes from the Immunology Database and Analysis Portal () database were included in this study. The immune signature was developed based on prognostic genes. The validation dataset was downloaded from the Gene Expression Omnibus (GEO) database.

RESULT

The immune signature namely immune-based prognostic score (IPRS) was developed with 229 genes. Multivariate analysis revealed that the IPRS was an independent prognostic factor for overall survival (OS) and progression-free survival (PFS) in patients with cervical cancer. Patients were stratified into high IPRS and low IPRS groups, and those in the high IPRS group were associated with better survival, which was validated in the validation set. A nomogram with IPRS and stage was constructed to predict mortality in cervical cancer.

CONCLUSIONS

We developed a robust prognostic signature IPRS that could be used to predict patients' survival outcome.

摘要

背景

宫颈癌是全球最常见的妇科恶性肿瘤类型之一。本研究旨在开发一种免疫特征以预测宫颈癌患者的生存情况。

方法

本研究纳入了来自癌症基因组图谱数据库（TCGA）的296例宫颈癌患者的基因表达数据以及来自免疫学数据库和分析门户（ImmPort）数据库的免疫相关基因。基于预后基因开发免疫特征。验证数据集从基因表达综合数据库（GEO）下载。

结果

利用229个基因开发了免疫特征，即基于免疫的预后评分（IPRS）。多变量分析显示，IPRS是宫颈癌患者总生存期（OS）和无进展生存期（PFS）的独立预后因素。患者被分为高IPRS组和低IPRS组，高IPRS组患者的生存期更好，这在验证集中得到了验证。构建了一个包含IPRS和分期的列线图以预测宫颈癌患者的死亡率。

结论

我们开发了一种可靠的预后特征IPRS，可用于预测患者的生存结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be87/8029986/e2c4d7bf9d35/fonc-11-616530-g001.jpg

相似文献

Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer.

Front Oncol. 2021 Mar 17;11:616530. doi: 10.3389/fonc.2021.616530. eCollection 2021.

A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.

Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022.

Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.

J Transl Med. 2020 Oct 7;18(1):380. doi: 10.1186/s12967-020-02545-z.

An Immune-Gene-Based Classifier Predicts Prognosis in Patients With Cervical Squamous Cell Carcinoma.

Front Mol Biosci. 2021 Jul 5;8:679474. doi: 10.3389/fmolb.2021.679474. eCollection 2021.

A Novel Immune-Related Signature to Predict Prognosis and Immune Infiltration of Cervical Cancer.

Med Sci Monit. 2023 Mar 28;29:e938660. doi: 10.12659/MSM.938660.

Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response.

Future Oncol. 2022 Mar;18(9):1055-1066. doi: 10.2217/fon-2021-0600. Epub 2022 Feb 2.

Prognosis analysis of necroptosis-related genes in colorectal cancer based on bioinformatic analysis.

Front Genet. 2022 Aug 15;13:955424. doi: 10.3389/fgene.2022.955424. eCollection 2022.

Construction of a Novel Immune-Related mRNA Signature to Predict the Prognosis and Immune Characteristics of Human Colorectal Cancer.

Front Genet. 2022 Mar 23;13:851373. doi: 10.3389/fgene.2022.851373. eCollection 2022.

Extracellular matrix-based gene signature for predicting prognosis in colon cancer and immune microenvironment.

Transl Cancer Res. 2023 Feb 28;12(2):321-339. doi: 10.21037/tcr-22-2036. Epub 2023 Feb 15.

A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.

Front Immunol. 2022 Jul 18;13:851622. doi: 10.3389/fimmu.2022.851622. eCollection 2022.

引用本文的文献

Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.

Cancer Immunol Immunother. 2023 May;72(5):1121-1138. doi: 10.1007/s00262-022-03316-z. Epub 2022 Nov 7.

Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma.

Cancer Cell Int. 2022 Oct 10;22(1):307. doi: 10.1186/s12935-022-02722-8.

DNA Damage Repair-Related Genes Signature for Immune Infiltration and Outcome in Cervical Cancer.

Front Genet. 2022 Mar 3;13:733164. doi: 10.3389/fgene.2022.733164. eCollection 2022.

Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations.

BMC Cancer. 2022 Feb 21;22(1):192. doi: 10.1186/s12885-022-09291-z.

Identifying a cervical cancer survival signature based on mRNA expression and genome-wide copy number variations.

Exp Biol Med (Maywood). 2022 Feb;247(3):207-220. doi: 10.1177/15353702211053580. Epub 2021 Oct 21.

Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration.

Front Cell Dev Biol. 2021 Jun 24;9:677831. doi: 10.3389/fcell.2021.677831. eCollection 2021.

本文引用的文献

mA regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer.

Mol Cancer. 2020 Mar 12;19(1):53. doi: 10.1186/s12943-020-01170-0.

Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.

J Cell Mol Med. 2020 Mar;24(5):2819-2831. doi: 10.1111/jcmm.14830. Epub 2020 Jan 29.

Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors.

Oncoimmunology. 2019 Oct 3;8(12):e1659094. doi: 10.1080/2162402X.2019.1659094. eCollection 2019.

The prognostic landscape of tumor-infiltrating immune cells in cervical cancer.

Biomed Pharmacother. 2019 Dec;120:109444. doi: 10.1016/j.biopha.2019.109444. Epub 2019 Sep 25.

Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer.

Sci Rep. 2019 Mar 1;9(1):3284. doi: 10.1038/s41598-019-39150-0.

Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.

EBioMedicine. 2019 Feb;40:318-326. doi: 10.1016/j.ebiom.2018.12.054. Epub 2018 Dec 27.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.

Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention.

Rheumatology (Oxford). 2018 Jul 1;57(suppl_5):v26-v33. doi: 10.1093/rheumatology/kex523.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.

Front Immunol. 2017 Sep 13;8:1124. doi: 10.3389/fimmu.2017.01124. eCollection 2017.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

基于免疫基因的宫颈癌预后标志物的开发与验证

Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer.

作者信息

Chen Yu, Lin Hao, Pi Ya-Nan, Chen Xi-Xi, Zhou Hu, Tian Yuan, Zhao Wei-Dong, Xia Bai-Rong

机构信息

Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Graduate School, Benbu Medical College, Benbu, China.